CN103889961A - 作为辣椒素类似物受体配体的携带被含氧基团取代的苯基的被取代的基于吡唑基的甲酰胺及脲衍生物 - Google Patents

作为辣椒素类似物受体配体的携带被含氧基团取代的苯基的被取代的基于吡唑基的甲酰胺及脲衍生物 Download PDF

Info

Publication number
CN103889961A
CN103889961A CN201280053470.3A CN201280053470A CN103889961A CN 103889961 A CN103889961 A CN 103889961A CN 201280053470 A CN201280053470 A CN 201280053470A CN 103889961 A CN103889961 A CN 103889961A
Authority
CN
China
Prior art keywords
phenyl
methyl
pyrazol
fluoro
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280053470.3A
Other languages
English (en)
Chinese (zh)
Inventor
R.弗兰克-福尔蒂恩
T.克里斯托弗
K.希内
J.德夫里
N.达曼
B.莱施
G.巴伦贝格
D.J.绍恩德斯
H.施托克豪森
金勇洙
金明燮
李智雨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MEDIFRON DBT CO Ltd
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Priority to CN201710970447.5A priority Critical patent/CN107739338A/zh
Publication of CN103889961A publication Critical patent/CN103889961A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
CN201280053470.3A 2011-11-09 2012-11-08 作为辣椒素类似物受体配体的携带被含氧基团取代的苯基的被取代的基于吡唑基的甲酰胺及脲衍生物 Pending CN103889961A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710970447.5A CN107739338A (zh) 2011-11-09 2012-11-08 作为辣椒素类似物受体配体的甲酰胺及脲衍生物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11008914 2011-11-09
EP11008914.1 2011-11-09
PCT/EP2012/072140 WO2013068461A1 (en) 2011-11-09 2012-11-08 Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an o-containing group as vanilloid receptor ligands

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710970447.5A Division CN107739338A (zh) 2011-11-09 2012-11-08 作为辣椒素类似物受体配体的甲酰胺及脲衍生物

Publications (1)

Publication Number Publication Date
CN103889961A true CN103889961A (zh) 2014-06-25

Family

ID=47143122

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280053470.3A Pending CN103889961A (zh) 2011-11-09 2012-11-08 作为辣椒素类似物受体配体的携带被含氧基团取代的苯基的被取代的基于吡唑基的甲酰胺及脲衍生物
CN201710970447.5A Pending CN107739338A (zh) 2011-11-09 2012-11-08 作为辣椒素类似物受体配体的甲酰胺及脲衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710970447.5A Pending CN107739338A (zh) 2011-11-09 2012-11-08 作为辣椒素类似物受体配体的甲酰胺及脲衍生物

Country Status (14)

Country Link
EP (1) EP2776398B1 (enExample)
JP (1) JP6189313B2 (enExample)
KR (1) KR101985442B1 (enExample)
CN (2) CN103889961A (enExample)
AR (1) AR088702A1 (enExample)
AU (1) AU2012334065B2 (enExample)
BR (1) BR112014011262B1 (enExample)
CA (1) CA2854932A1 (enExample)
ES (1) ES2823577T3 (enExample)
HK (1) HK1201839A1 (enExample)
IN (1) IN2014KN00849A (enExample)
MX (1) MX2014005610A (enExample)
TW (1) TW201326133A (enExample)
WO (1) WO2013068461A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113135856A (zh) * 2021-04-08 2021-07-20 天津大学 一类3-三氟甲基-5-氰基吡唑化合物及其制备方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016096140A1 (en) * 2014-12-19 2016-06-23 Grünenthal GmbH Process for the preparation of 1-[(heteroaryl)-methyl]- or 1-[(aryl)-methyl]-3-[4-(hydroxymethyl)-phenyl]-ureas
EP3438090A4 (en) * 2016-03-31 2019-09-04 FUJIFILM Toyama Chemical Co., Ltd. NOVEL PROCESS FOR PRODUCING HYDROXAMIC ACID DERIVATIVE AND CORRESPONDING INTERMEDIATE
US11492318B2 (en) * 2017-05-19 2022-11-08 Etna-Tec, Ltd. Methods for making functionalized fluorinated monomers, fluorinated monomers, and compositions for making the same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005314407A (ja) * 2004-03-31 2005-11-10 Nippon Nohyaku Co Ltd 新規なハロアルキルスルホンアニリド誘導体、除草剤及びその使用方法並びにその中間体
CN101331124A (zh) * 2005-10-19 2008-12-24 格吕伦塔尔有限公司 新颖的辣椒素受体配体和它们用于生产药物的用途
WO2010127856A1 (en) * 2009-05-07 2010-11-11 Grünenthal GmbH Substituted phenyllureas and phenylamides as vanilloid receptor ligands
WO2011109441A1 (en) * 2010-03-01 2011-09-09 Myrexis, Inc. Compounds and therapeutic uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012910A1 (en) * 1997-09-11 1999-03-18 Nissan Chemical Industries, Ltd. Pyrazole compounds and plant disease control agent
EP1684762A4 (en) * 2003-11-13 2009-06-17 Ambit Biosciences Corp UREA DERIVATIVES AS MODULATORS OF KINASE
US7998995B2 (en) * 2006-12-08 2011-08-16 Exelixis Patent Company Llc LXR and FXR modulators
DE102007018151A1 (de) * 2007-04-16 2008-10-23 Günenthal GmbH Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
PL2427436T3 (pl) 2009-05-07 2013-06-28 Gruenenthal Gmbh Podstawione aromatyczne pochodne karboksamidu i mocznika jako ligandy receptora waniloidowego

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005314407A (ja) * 2004-03-31 2005-11-10 Nippon Nohyaku Co Ltd 新規なハロアルキルスルホンアニリド誘導体、除草剤及びその使用方法並びにその中間体
CN101331124A (zh) * 2005-10-19 2008-12-24 格吕伦塔尔有限公司 新颖的辣椒素受体配体和它们用于生产药物的用途
WO2010127856A1 (en) * 2009-05-07 2010-11-11 Grünenthal GmbH Substituted phenyllureas and phenylamides as vanilloid receptor ligands
WO2011109441A1 (en) * 2010-03-01 2011-09-09 Myrexis, Inc. Compounds and therapeutic uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113135856A (zh) * 2021-04-08 2021-07-20 天津大学 一类3-三氟甲基-5-氰基吡唑化合物及其制备方法

Also Published As

Publication number Publication date
EP2776398B1 (en) 2020-09-02
EP2776398A1 (en) 2014-09-17
HK1201839A1 (en) 2015-09-11
BR112014011262A2 (pt) 2017-04-25
AU2012334065A1 (en) 2014-05-22
BR112014011262A8 (pt) 2018-03-06
MX2014005610A (es) 2014-07-30
KR101985442B1 (ko) 2019-06-03
CA2854932A1 (en) 2013-05-16
AU2012334065B2 (en) 2017-06-08
ES2823577T3 (es) 2021-05-07
IN2014KN00849A (enExample) 2015-10-02
BR112014011262B1 (pt) 2022-02-15
AR088702A1 (es) 2014-06-25
KR20140091043A (ko) 2014-07-18
TW201326133A (zh) 2013-07-01
JP2014532741A (ja) 2014-12-08
WO2013068461A1 (en) 2013-05-16
CN107739338A (zh) 2018-02-27
JP6189313B2 (ja) 2017-08-30

Similar Documents

Publication Publication Date Title
US9624209B2 (en) Substituted phenylureas and phenylamides as vanilloid receptor ligands
CN119490431A (zh) Tead转录因子的新型小分子抑制剂
JP6183451B2 (ja) ２−アシルアミノチアゾール誘導体またはその塩
KR20080080195A (ko) 크로메인 치환된 벤즈이미다졸 및 이들의 산 펌프억제제로서의 용도
JP2012526062A (ja) バニロイド受容体リガンドとしての置換フェニル尿素および置換フェニルアミド
CA3208103A1 (en) Anti-viral compounds
JP5250627B2 (ja) 新規化合物
JP2013534229A (ja) バニロイド受容体リガンドとしての置換された環状カルボキサミド誘導体および尿素誘導体
AU2005316034B2 (en) Triazole substituted aminobenzophenone compounds
EA008801B1 (ru) Получение арилалкилкарбаматных производных и их применение в терапии
JP2014532746A (ja) バニロイド受容体リガンドとしての、ｃｏ含有基で置換されたフェニル部分を担持する置換ピラゾリルをベースとするカルボキサミドおよび尿素誘導体
CN103889961A (zh) 作为辣椒素类似物受体配体的携带被含氧基团取代的苯基的被取代的基于吡唑基的甲酰胺及脲衍生物
KR20150085045A (ko) 3-아미노시클로펜탄 카르복사미드 유도체
KR20140091041A (ko) 바닐로이드 수용체 리간드로서의 so2-함유 그룹으로 치환된 페닐 모이어티를 갖는 치환된 피라졸릴계 카복사미드 및 우레아 유도체들
CN103906736A (zh) 作为类香草素受体配体的具有被含n-基团取代的苯基基团的被取代的基于吡唑基的羧酰胺和脲衍生物
EP3130589A1 (en) Heterocyclic aza compounds
CN102803258B (zh) 烷基-杂环氨基甲酸酯衍生物，它们的制备和治疗应用
JP2014532743A (ja) バニロイド受容体リガンドとしての、ｎ−環式基で置換されたフェニル部分を担持する置換ピラゾリルをベースとするカルボキサミドおよび尿素誘導体
HK1117152A1 (en) Triazole substituted aminobenzophenone compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20170522

Address after: Seoul, South Kerean

Applicant after: MEDIFRON DBT CO., LTD.

Address before: Germany a Xing

Applicant before: Gruenenthal GmbH

TA01 Transfer of patent application right
RJ01 Rejection of invention patent application after publication

Application publication date: 20140625

RJ01 Rejection of invention patent application after publication